Loading
Loading…
Loading…
| # | Schedule | Awarded To | Bids | Value |
|---|---|---|---|---|
| 1 | Schedule 1 | FLORENCE INDIALikely | 1 | ₹69,142.50 |
| 2 | Schedule 2 | R K TRADING COLikely | 1 | ₹162 |
| 3 | Schedule 3 | R K TRADING COLikely | 1 | ₹112 |
| 4 | Schedule 4 | DEEKNISC SERVICES & SOLUTIONS PRIVATE LIMITEDLikely | 4 | ₹1,703 |
| 5 | Schedule 5 | MEDICARESLikely | 1 | ₹10,290 |
Tender Value
₹10.3 L
EMD Value
Exempted
Closing Date
22 May 2025, 10:00 amClosed
D IFA RE 21 Human Insulin Analogue Long acting basal Inj 100 IU ml Recombinant DNA origin 300 IU Disposable Pen with 5 needles per pen
D IFA RE 21 Gliclazide MR 30 mg Tab
D IFA RE 21 Glipizide 5mg Tab
D IFA RE 21 Sitagliptin 50 mg Metformin 1000 mg Tab
D IFA RE 21 Insulin Lispro Biphasic injection I DOT P 25 Insulin Lispro and 75 Insulin Lispro protamine suspension
D IFA RE 21 Sirolimus 1mg Tab
D IFA RE 21 Pioglitazone Hydrochloride 15mg Tab
D IFA RE 21 Alendronate Sodium 70mg Tab
D IFA RE 21 Neostigmine 0 DOT 5mg 1ml Inj
D IFA RE 21 Cisatracurium 2 mg ml Inj 10ml vial
D IFA RE 21 Tacrolimus 1mg Prolonged Release Cap
D IFA RE 21 Mycophenolate Mofetil 750mg Tab
D IFA RE 21 Intravenous Immunoglobulin IvIg 10gm Bott of 50ml
D IFA RE 21 Calcium Phosphate 0 DOT 24 mg 5 ml Syp
D IFA RE 21 Calcium Acetate 500 mg Tab
D IFA RE 21 Carnitine 200 mg Tab
D IFA RE 21 Acyclovir Ophth Ointment 3 w w in 5 gm tube
D IFA RE 21 Ciprofloxacin HCl 0 DOT 3 Tube of 5 gm
D IFA RE 21 Ciprofloxacin HCl 0 DOT 3 Dexamethasone DOT 1 bott of 5ml
D IFA RE 21 Cyclosporine eye drop 0 DOT 05 bott of 3 ml
D IFA RE 21 Fluorescein Sodium 20 3 ml Inj
D IFA RE 21 Flurbiprofen Sodium ophthalmic soln 0 DOT 03 vial of 5 ml
D IFA RE 21 Homatropine Hydrochloride Soln 2
D IFA RE 21 Ketorolac Tromethamine 0 DOT 4 Eye drops
D IFA RE 21 Natamycin 3 eye drops in 3 ml bott
D IFA RE 21 Carboxy Methyl Cellulose CMC 1 Gel
D IFA RE 21 Ofloxacin 0 DOT 3 bott of 5 ml
D IFA RE 21 Pilocarpine Nitrate eye solution 2 bott of 5 ml
D IFA RE 21 Pilocarpine Intracameral Inj 0 DOT 5 Pilocarpine nitrate intra ocular Inj without preservatives amp of 01ml each
D IFA RE 21 Prednisolone acetate 1 w v bott of 5 ml
D IFA RE 21 Sodium Chloride 6 w w ointment Tube of 3 gm
D IFA RE 21 Azelaic acid 20 cream tube of 15 gm
D IFA RE 21 Cream Luliconazole tube of 15 gm
D IFA RE 21 Tobramycin 0 DOT 3 bott of 5 ml
D IFA RE 21 Tropicamide 1 with 5 Phenylephrine eye drops bott of 5 ml
D IFA RE 21 Tropicamide Eye solution 1 bott of 5 ml
D IFA RE 21 Trypan Blue 0 DOT 6 Inj in vial of 1ml
D IFA RE 21 Amphotericin B 0 DOT 5 eye drops bott of 5 ml
D IFA RE 21 Atropine Sulphate 1 w v Eye Drop Bott of 3 ml
D IFA RE 21 Atropine Sulphate Oint 1 Tube of 3gm
D IFA RE 21 Olopatadine Hydrochloride 0 DOT 1 Ophthalmic Soln Bott of 5ml
D IFA RE 21 Olopatadine 0 DOT 2 Ophthalmic Soln bott of 5 ml
D IFA RE 21 Proparacaine Eye Drops 0 DOT 5 Bott of 5 ml
D IFA RE 21 Moxifloxacin HCl 0 DOT 5 and Dexamethasone 0 DOT 1 Ophthalmic Soln Bott of 5ml
D IFA RE 21 Diphenhydramine 10 15 mg per 5 ml and Ammonium Chloride 100 150 mg Sodium Citrate 50 85 mg per 5ml Syp Bott of 100ml
D IFA RE 21 Beclomethasone Dipropionate nasal spray 50 mcg per dose metered dose 150 units
D IFA RE 21 Betahistine Dihydrochloride 16mg Tab
D IFA RE 21 Clotrimazole 1 w v IP Lignocaine 2 w v IP ear drop bott of 10ml
D IFA RE 21 Chloramphenicol 5 w v Clotrimazole 1 w v Betamethasone 0 DOT 25 w v Lignocaine HCl 2 w v in bott of 5 ml
D IFA RE 21 Xylometazoline HCl 0 DOT 05 w v nasal solution for paed use bott of 10ml Bid Details 2/46
7757124
GEM/2025/B/6155775
Two Packet Bid
D IFA RE 21 Human Insulin Analogue Long acting basal Inj
30 days
West Bengal; Darjeeling
Item wise evaluation
BOQ
8 documents required · 8 mandatory
3 yrs
₹3
80%
Exempted
22 May 2025
30 Apr 2025
22 May 2025
| Item No | Item Title | Description | Qty | Unit | Consignee | Delivery (days) | Spec |
|---|---|---|---|---|---|---|---|
| 1 | D IFA RE 21 Human Insulin Analogue Long acting basal Inj 100 IU ml Recombinant DNA origin 300 IU Disposable Pen with 5 needles per pen | Human Insulin Analogue Long acting basal Inj 100 IU ml Recombinant DNA origin 300 IU Disposable Pen with 5 needles per pen | 150 | Pen | Darjeeling | 30 | |
| 2 | D IFA RE 21 Gliclazide MR 30 mg Tab | Gliclazide MR 30 mg Tab | 100 | No | Darjeeling | 30 | |
| 3 | D IFA RE 21 Glipizide 5mg Tab | Glipizide 5mg Tab | 100 | No | Darjeeling | 30 | - |
| 4 | D IFA RE 21 Sitagliptin 50 mg Metformin 1000 mg Tab | Sitagliptin 50 mg Metformin 1000 mg Tab | 1,300 | No | Darjeeling | 30 | |
| 5 | D IFA RE 21 Insulin Lispro Biphasic injection I DOT P 25 Insulin Lispro and 75 Insulin Lispro protamine suspension | Insulin Lispro Biphasic injection I DOT P 25 Insulin Lispro and 75 Insulin Lispro protamine suspension | 10 | PFP PFS | Darjeeling | 30 | - |
| 6 | D IFA RE 21 Sirolimus 1mg Tab | Sirolimus 1mg Tab | 1,500 | No | Darjeeling | 30 | |
| 7 | D IFA RE 21 Pioglitazone Hydrochloride 15mg Tab | Pioglitazone Hydrochloride 15mg Tab | 1,200 | No | Darjeeling | 30 | - |
| 8 | D IFA RE 21 Alendronate Sodium 70mg Tab | Alendronate Sodium 70mg Tab | 300 | No | Darjeeling | 30 | |
| 9 | D IFA RE 21 Neostigmine 0 DOT 5mg 1ml Inj | Neostigmine 0 DOT 5mg 1ml Inj | 750 | Amp Vial | Darjeeling | 30 | - |
| 10 | D IFA RE 21 Cisatracurium 2 mg ml Inj 10ml vial | Cisatracurium 2 mg ml Inj 10ml vial | 20 | Vial | Darjeeling | 30 |
Tap a document below to read it instantly. You can also download everything as a ZIP if you prefer.
bid_7757124.pdf
GEM_BID
item_specification_ifa_re-21_2025-04-21-15-48-36_0d44f356b26fee90e4ec2740e7efa8cc.pdf
BOQ
boq_item_sample_file_2_2025-04-21-15-48-36_7ca510ec455e0f9778153cac4c656161.csv
BOQ
1745231089.xlsx
OTHER
DOCUMENTS_b16d050a-b8a6-4919-90ee1745231543751_arnair.docx
OTHER
list-of-categories-where-trials-are-allowed_1712126171.pdf
OTHER
gtc.pdf
OTHER
Download all tender documents and submit your bid
Disclaimer: TenderKart has made every reasonable effort to ensure that the information on this page is accurate and authentic, however it cannot be held liable for any third-party claims or losses or any damages. TenderKart makes no warranty, expressed or implied, as to the results obtained from the use of this information. If you notice any error or omission, please let us know at .